All News

Found 624,603 articles

• Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

  9/18/2020

  Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix

• CardieX Granted Patent in Europe for Key Brachial Cuff Blood Pressure Technology

  9/18/2020

   CardieX Limited (ASX: CDX ) (CardieX, the Company) announced today that CardieX subsidiary ATCOR was granted a new patent by the European Patent Office (EPO) for the Company's proprietary SphygmoCor® technology used in cuff-based blood pressure devices. EPO Patent Number EP2566387 further protects the company's intellectual

• Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes

  9/18/2020

  Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S. Wessels to the newly created position of Chief Commercial Officer

• National Kidney Foundation Statement on the ESRD Treatment Choices Model (ETC) and Policies to Improve Kidney Patient Choice

  9/18/2020

  "The National Kidney Foundation (NKF) is pleased to support the three linchpin policies of the Advancing American Kidney Health (AAKH) initiative finalized this morning. On behalf of 37 million adults in the U.S. affected by kidney disease, we e

• Emily Leproust, Ph.D., to Receive 2020 Rosalind Franklin Award

  9/18/2020

  Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its CEO and co-founder, Emily M. Leproust, Ph.D., will receive the 2020 Rosalind Franklin Award for Leadership at the Biotechnology Innovation Organization (BIO) IMPACT conference.

• Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors

  9/18/2020

  Phosplatin Therapeutics presented data from a Phase 1b dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with avelumab, a PD-L1 immune checkpoint inhibitor, in patients with progressing solid tumors who previously exhausted all available treatment options.

• Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain CancersResults include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)

  9/18/2020

  Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38 for BMBC and rGBM, respectively, and produced partial responses in both cohorts of brain cancer patients.

• StageZero Life Sciences Announces Share Consolidation Completion

  9/18/2020

  StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Corporation") announced that trading of the common shares on the TSX on a post-Consolidation basis commences at market open on September 18, 2020.

• Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress

  9/18/2020

  Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors.

• Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress

  9/18/2020

  Successfully completed IPO in August 2020 raising $76.6 million in gross proceeds On track to initiate planned new clinical trials in melanoma and head and neck cancer

• Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress

  9/18/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or metastatic urothelial carcinoma.

• Progenity Announces Addition to Russell 2000® Index

  9/18/2020

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will be added to the Russell 2000®  Index, effective when the U.S. market opens on Friday, September 18, 2020.

• RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System

  9/18/2020

  Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System in New York City.

• VERTESS Stampedes Past COVID-19 Hurdle, Closes 4 Deals in Q2/Q3 2020

  9/18/2020

  VERTESS (www.vertess.com), a leading healthcare mergers and acquisitions (M&A) advisory firm, today announced the closing of four major Durable Medical Equipment (DME) healthcare transactions in Q2 and Q3 2020, despite challenges brought on by the pandemic.

• Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study

  9/18/2020

  Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020   [18-September-2020]   SEATTLE and VANCOUVER,

• BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020

  9/18/2020

  BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, today announced late-breaking clinical results of the Cooral® System, a novel cooling device for the prevention of Oral Mucositis (OM), at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

• Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of DirectorsIndustry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board

  9/18/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.

• Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

  9/18/2020

  Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced its addition as a member of the US small-cap Russell 2000® Index,

• Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics

  9/18/2020

  OncXerna’s RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients

• Radient Conducts Strategic Review of Operations and Announces Management Changes

  9/18/2020

  Radient Technologies Inc. (“Radient” or the “Company”) (TSX-V:RTI; OTCQX:RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, announces its Board of Directors (the “Board”) is conducting a strategic review of the Company’s operations targeting a path to positive cash flow by evaluating costs and under utilized assets.